SCM
KPRX icon

Stonepine Capital Management’s Kiora Pharmaceuticals KPRX Stock Holding History

Stonepine Capital Management’s Portfolio KPRX Stock Details KPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-131,144
Closed -$258K – 93
2025
Q4 		$258K Sell
131,144
-9,454
-7% -$21.6K 0.19% 58
2025
Q3 		$391K Sell
140,598
-37,402
-21% -$103K 0.32% 46
2025
Q2 		$513K Sell
178,000
-22,647
-11% -$69K 0.5% 40
2025
Q1 		$604K Sell
200,647
-323
-0.2% -$1.12K 0.59% 35
2024
Q4 		$663K Sell
200,970
-1,430
-0.7% -$4.94K 0.54% 37
2024
Q3 		$741K Buy
202,400
+2,400
+1% +$9.36K 0.47% 30
2024
Q2 		$840K Buy
+200,000
New +$933K 0.77% 16

Other funds holding KPRX

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
RC
Rangeley Capital New Canaan, Connecticut $103M AUM 77.32% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Stonepine Capital Management's KPRX Position: Q1 2026 in Review

Stonepine Capital Management sold out of Kiora Pharmaceuticals (KPRX) in Q1 2026, closing a stake of 131,144 shares — an estimated $258K sold.

Stonepine Capital Management first reported a position in KPRX in Q2 2024 and held it in 7 quarters. The position peaked at $840K in Q2 2024. 18 funds tracked by Wall St. Rank hold KPRX as of Q1 2026.

  • Stonepine Capital Management reported no remaining Kiora Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Stonepine Capital Management sold 131,144 Kiora Pharmaceuticals shares in Q1 2026, an estimated $258K.
  • Stonepine Capital Management first reported a position in Kiora Pharmaceuticals in Q2 2024 and held it in 7 quarters.
  • Stonepine Capital Management's Kiora Pharmaceuticals position peaked at $840K in Q2 2024.
  • 18 funds tracked by Wall St. Rank held Kiora Pharmaceuticals as of Q1 2026.

Based on Stonepine Capital Management's 13F filing for Q1 2026, filed 14 May 2026.